|Articles|April 1, 2004
Solution could control inflammation in less time
Irvine, CA-ISTA Pharmaceuticals Inc. plans to file a new drug application with the FDA during the second quarter of 2004 for its 0.1% bromfenac sodium ophthalmic solution (Xibrom). The topical, twice-daily, non-steroidal, anti-inflammatory solution is being developed for the treatment of ocular inflammation after cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























